Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era

被引:40
作者
Sun, L
Gancarczyk, K
Paquette, EL
McLeod, DG
Kane, C
Kusuda, L
Lance, R
Herring, J
Foley, J
Baldwin, D
Bishoff, JT
Soderdahl, D
Wu, HY
Xu, L
Moul, JW
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA
[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[3] San Diego Naval Med Ctr, San Diego, CA USA
[4] Portsmouth Naval Med Ctr, Portsmouth, Hants, England
[5] Madigan Army Med Ctr, Tacoma, WA 98431 USA
[6] Natl Naval Med Res Inst, Bethesda, MD USA
[7] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[8] Malcolm Grow Med Ctr, Andrews AFB, MD USA
[9] Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA
[10] Eisenhower Army Med Ctr, Ft Gordon, GA USA
来源
UROLOGIC ONCOLOGY | 2001年 / 6卷 / 05期
关键词
prostate cancer; database; epidemiology; disease-free survival;
D O I
10.1016/S1078-1439(01)00145-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Center for Prostate Disease Research (CPDR) database was developed to standardize the clinical procedures for patients with carcinoma of the prostate (CaP), and support retrospective and prospective studies on CaP within the military health care system. METHODS: A set of clinical forms recording diagnosis, treatments, follow-up, and necropsy information for CaP management was developed. A relational database with about 500 data fields for recording CaP status, clinical intervention and outcome was developed and installed in nine military facilities. As a demonstration of utility, the ages at diagnosis and death from CaP over the past 15 years were analyzed. RESULTS: As of the end of November 2000, the database has archived 242,227 records on 11,637 men. The mean number of follow-up visits per patient is presently 8.45 (98,323 total follow-up visits). A greater than 50% reduction in prostate cancer mortality was demonstrated. Dead/alive ratio is 21.1%. Prostate cancer specific mortality represents 30.1% of the total death population. The mean age at diagnosis decreased from 68.0 years in 1991 to 64.7 in 1999 (p<0.05). The age at death increased from 68.8 years before 1986 to 78.0 in 2000 (p<0.01). Mean surviving months between diagnosis and death is increased from 33.2 months before 1986 to 108.2 in 2000 (p<0.01). CONCLUSION: The CPDR database is suitable for analyzing epidemiological features of CaP, treatment efficacy, and for monitoring the quality of life of CaP patients. CaP detection and outcome is significantly improved in our military health care beneficiaries since the introduction of PSA and increased public awareness. Our goal is to accrue 20,000 men and follow them for 20 years. (C) 2001 Elsevier Science, Inc. All rights reserved.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 22 条
[1]  
*AM CANC SOC, 1999, FACTS FIG
[2]  
Amling CL, 1998, MAYO CLIN PROC, V73, P401
[3]   Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer [J].
Bauer, JJ ;
Connelly, RR ;
Seterhenn, IA ;
Deausen, J ;
Srivastava, S ;
McLeod, DG ;
Moul, JW .
JOURNAL OF UROLOGY, 1998, 159 (03) :929-933
[4]   Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer [J].
Bauer, JJ ;
Connelly, RR ;
Seterhenn, IA ;
Srivastava, S ;
McLeod, DG ;
Moul, JW .
MILITARY MEDICINE, 1998, 163 (09) :615-619
[5]   Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer [J].
Blute, ML ;
Bergstralh, EJ ;
Partin, AW ;
Walsh, PC ;
Kattan, MW ;
Scardino, PT ;
Montie, JE ;
Pearson, JD ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2000, 164 (05) :1591-1595
[6]  
Dennis LK, 2000, PROSTATE, V42, P247
[7]   National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening [J].
Farkas, A ;
Schneider, D ;
Perrotti, M ;
Cummings, KB ;
Ward, WS .
UROLOGY, 1998, 52 (03) :444-448
[8]   Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction [J].
Gao, CL ;
Dean, RC ;
Pinto, A ;
Mooneyhan, R ;
Connelly, RR ;
McLeod, DG ;
Srivastava, S ;
Moul, JW .
JOURNAL OF UROLOGY, 1999, 161 (04) :1070-1076
[9]   INCIDENCE OF PROSTATE-CANCER DIAGNOSIS IN THE ERAS BEFORE AND AFTER SERUM PROSTATE-SPECIFIC ANTIGEN TESTING [J].
JACOBSEN, SJ ;
KATUSIC, SK ;
BERGSTRALH, EJ ;
OESTERLING, JE ;
OHRT, D ;
KLEE, GG ;
CHUTE, CG ;
LIEBER, MM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (18) :1445-1449
[10]   Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database [J].
Koppie, TM ;
Grossfeld, GD ;
Miller, D ;
Yu, J ;
Stier, D ;
Broering, JM ;
Lubeck, D ;
Henning, JM ;
Flanders, SC ;
Carroll, PR .
JOURNAL OF UROLOGY, 2000, 164 (01) :81-88